CorMedix Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 6 of 6 Posts
Is CorMedix Overvalued?
Article By: Modest Money Tuesday, April 2, 2019 6:54 PM EDT
The stock has returned 56% year-to-date. It is currently trading at price to sales ratio of 574.17 and P/B ratio of 41.92.
In this article: CRMD
Read
Four Best Biotech Stocks Of The First Quarter Of 2016
Article By: Zacks Investment Research Sunday, April 3, 2016 7:19 AM EDT
The entry of the first FDA-approved biosimilar, Zarxio, a biosimilar version of Amgen’s blockbuster drug, Neupogent, last year has left biotech companies vying to enter this high revenue generating space. Biosimilars are the next big thing.
In this article: KIN, CRMD, ALIOF, MESO Also: AMGN, GILD, SHPG, BXLT
Read
Seven Biotech Names On The Upswing: 2016 Small-Cap Biotech Watchlist Update
Article By: The Life Sciences Report Wednesday, March 9, 2016 5:47 PM EDT
Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China.
In this article: SGYP, CRMD, ORMP, SRNE, ARRY, PTIE, AGEN, GALE, PPHM, EVOK, ADMA, AKBA, KPTI, VSTM, AST, RXDX, AGTC, WVE, FATE, FLKS, PIRS, ABEO
Read
The 2016 Small-Cap Biotech Watchlist Debuts At The Biotech Showcase
Article By: The Life Sciences Report Wednesday, January 27, 2016 6:16 PM EDT
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good producing value for investors.
In this article: AZN, NVO, SGYP, SNY, CRMD, ORMP, CMXHY, SRNE, ALNY, ARRY, INCY, IRWD, PTIE, REGN, VRTX, AGEN, GALE, GRFS, PPHM, EVOK, ADMA, AKBA, VSTM, AST, RXDX, AGTC, NK, WVE, FATE, FLKS
Read
Celgene Beats On Q1 Earnings, Misses Revenues, Keeps View
Article By: Zacks Investment Research Thursday, April 30, 2015 3:00 PM EDT
Despite income up more than 150% and revenues up 20%, lower GAAP EPS guidance contributes to 4% drop in stock so far Thursday.
In this article: CELG, PSTV, BIIB, CRMD
Read
CRMD Announces FDA IND Filing For Neutrolin; ZFGN Completes Enrollment Of Phase 2a Trial Of Beloranib
Article By: BioMedReports Friday, September 26, 2014 6:58 AM EDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease.
In this article: CRMD, ZFGN
Read
1 to 6 of 6 Posts